miRdetect GmbH

The number of cancer patients is rapidly increasing worldwide and an early detection of cancer is becoming more and more important. Early detection dramatically increases the probability for higher survival rates and ultimately curing cancer. Furthermore adoption of liquid biopsies for patients with advanced malignancies is very important. But current approaches are not sensitive, specific, and reliable enough.

miRdetect has developed an innovative test procedure that enables the early and exact detection of cancer. This is applicable to genetic material of any origin and has the potential for highly sensitive and robust molecular diagnostic assays. The method has been validated through a testicular cancer assay as a first example.